Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Pivotal Trial of LiPlaCis in Patients with Metastatic Breast Cancer

X
Trial Profile

A Phase III Pivotal Trial of LiPlaCis in Patients with Metastatic Breast Cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Cadila Pharmaceuticals
  • Most Recent Events

    • 30 Aug 2019 According to an Oncology Venture media release, On June 3 company announced that the US FDA had provided its initial response to the IND application and this proposed study.The FDA has requested some additional testing of LiPlaCis related to the product characterization. Company expects to have these additional tests completed in good time before initiation of the study. The study design will be adapted to accommodate FDAs recommendation.
    • 15 Aug 2019 According to an Oncology Venture A/S media release, US Food & Drug administration (FDA) has approved an IDE (Investigational Device Exemption) application for use of the companys drug response predictor LiPlaCis DRP
    • 15 Aug 2019 According to an Oncology Venture A/S media release, the U.S. FDA is evaluating Oncology Venture IND (Investigational New Drug) application for the drug substance LiPlaCis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top